Clinical characteristics of patients with MF who responded to CEP-701
| Patient no. . | Sex/age, y . | Prior treatment . | Hemoglobin (g/dL) . | WBC (× 109/L) . | Platelets (× 109/L) . | Spleen, cm . | JAK2V617F allele burden, percentage . | Karyotype . | Cycles to response, mo . | Response and response duration, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female/61 | Hydroxyurea, anagrelide | 13.3 | 39.2 | 457 | 9 | 94.5 | Diploid | 3 | CI (spleen) 3+ |
| 2 | Male/59 | Erythropoietin | 8.9* | 3.8 | 66 | 0 | 42.1 | Insufficient yield | 1 | CI (hemoglobin) 22+ |
| 3 | Male/56 | Lenalidomide | 13 | 19.7 | 223 | 13 | 68.7 | 46, XY, del 13(q12;q22)[3] | 3 | CI (spleen) 19+ |
| 4 | Female/70 | IFN, thalidomide, lenalidomide, erythropoietin, prednisone | 10 | 14.9 | 70 | 21 | 40.2 | 46, X, t(X;1)(q11;p31), del(13)(q12q22)[11]; 46,XX,del(20) (q11q13)[9] | 4 | CI (spleen) 5 |
| 5 | Female/71 | Chlorambucil, hydroxyurea, thalidomide, lenalidomide, anagrelide, erythropoietin | 8.4* | 1.6 | 22 | 10 | 30 | 46,XX,del(4) (q21q33) [7]; 46,X,del(X) (q22q28) [6]; 46,XX,add(3) (q27), del(3) (q21q26.2), del(5) (q31q35), del(6) (p21p23), add(20) (q13) [2]; 46,XX,del(2) (p11p25) [1] | 1 | CI (absolute neutrophil count, spleen, platelets) 14 |
| 6 | Male/60 | Hydroxyurea, anagrelide, darbepoietin | 9.5* | 11.7 | 216 | 0 | 72.2 | Diploid | 9 | CI (hemoglobin) 12 |
| Patient no. . | Sex/age, y . | Prior treatment . | Hemoglobin (g/dL) . | WBC (× 109/L) . | Platelets (× 109/L) . | Spleen, cm . | JAK2V617F allele burden, percentage . | Karyotype . | Cycles to response, mo . | Response and response duration, mo . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Female/61 | Hydroxyurea, anagrelide | 13.3 | 39.2 | 457 | 9 | 94.5 | Diploid | 3 | CI (spleen) 3+ |
| 2 | Male/59 | Erythropoietin | 8.9* | 3.8 | 66 | 0 | 42.1 | Insufficient yield | 1 | CI (hemoglobin) 22+ |
| 3 | Male/56 | Lenalidomide | 13 | 19.7 | 223 | 13 | 68.7 | 46, XY, del 13(q12;q22)[3] | 3 | CI (spleen) 19+ |
| 4 | Female/70 | IFN, thalidomide, lenalidomide, erythropoietin, prednisone | 10 | 14.9 | 70 | 21 | 40.2 | 46, X, t(X;1)(q11;p31), del(13)(q12q22)[11]; 46,XX,del(20) (q11q13)[9] | 4 | CI (spleen) 5 |
| 5 | Female/71 | Chlorambucil, hydroxyurea, thalidomide, lenalidomide, anagrelide, erythropoietin | 8.4* | 1.6 | 22 | 10 | 30 | 46,XX,del(4) (q21q33) [7]; 46,X,del(X) (q22q28) [6]; 46,XX,add(3) (q27), del(3) (q21q26.2), del(5) (q31q35), del(6) (p21p23), add(20) (q13) [2]; 46,XX,del(2) (p11p25) [1] | 1 | CI (absolute neutrophil count, spleen, platelets) 14 |
| 6 | Male/60 | Hydroxyurea, anagrelide, darbepoietin | 9.5* | 11.7 | 216 | 0 | 72.2 | Diploid | 9 | CI (hemoglobin) 12 |
CI indicates clinical improvement.
Patients were transfusion-dependent.